Last week, the Australian government and the Indo-Pacific Centre for Health Security convened practitioners, researchers, educators, and decision-makers across the fields of public health, medicine, veterinary science, agriculture, government, defense, and anthropology for the first Global Health Security Conference in Sydney to examine the progress made to date in strengthening health systems and to identify gaps and opportunities for enhancing the international community’s ability to respond more efficiently and effectively to future health crises.
A “who’s who” of politicians, philanthropists, CEOs, and civil society leaders descended upon New York City this week for the annual United Nations General Assembly (UNGA). GHTC was there, serving as your eyes and ears on the ground. Here is what we heard and our top four takeaways on global health R&D.
Tackling malaria in the Brazilian Amazon has proved challenging. But furtunetly, a solution could be in sight.
As the year comes to an end, GHTC is reflecting on the top stories in global health innovation that made news in 2017.
As we close out our 10th anniversary year, we wanted to take a moment to reflect on our shared progress and celebrate the headlines and moments that shaped global health R&D over the past decade. Check out some of the highlights...
On April 28, senior leaders from government, the private sector, and the global health community came together in Berlin for a lively discuss on how the G20 can advance global health innovation to drive sustainable development and health security.
Scientists are exploring new open innovation and open source approaches to catalyze malaria drug development and move us closer to achieving the goal of ending malaria for good.
As the year comes to an end, GHTC is reflecting on the top stories in global health innovation that made news 2016.
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
When existing market forces alone fall short in ensuring availability of and access to lifesaving health tools, a range of interventions are needed to alter the market and ultimately change the behavior of its actors.
On Tuesday, GHTC launched our seventh annual policy report through a congressional briefing and panel discussion. The critical role played by the US government in catalyzing global health research and development was a recurring theme, as panelists discussed the interconnectedness of global and American health and emphasized the need for new health tools to protect against outbreaks and continue progress.
A vaccine candidate against Rift Valley Fever appears to be safe and effective for livestock and has the potential for use in humans.
As 2015 draws to a close, the Global Health Technologies Coalition is reflecting on the past year in global health innovation.
Global Health Now took an in-depth look at the flesh-eating fungus mycetoma—which enters the body through cuts, and can result in swollen, deformed limbs—in a three-part series on this Untold Global Health Story of 2015.
After four successful Phase 3 clinical trials enrolling more than 3,500 patients in 18 countries, the European Medicines Agency (EMA) has granted Pyramax® Granules, a pediatric malaria medicine, a positive opinion under Article 58—a mechanism through which the EMA reviews and issues a scientific opinion on products that are not intended for use in Europe.
Breast milk is the perfect first food for newborns; it provides nutrients and energy that infants need and contains substances that strengthen their immune systems.
The Drugs for Neglected Disease initiative (DNDi) and the Medicines for Malaria Venture (MMV)—nonprofit product development partnerships (PDPs) and members of the Global Health Technologies Coalition—have teamed up to ensure two treatments for malaria continue to reach the patients who need them most.